ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2025
Trichophyton mentagrophytes type VII: cohort study on patient characteristics, clinical features, disease course, and treatment.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trichophyton mentagrophytes Genotype VII: Sexually Transmitted Infection Beyond MSM.The Australasian journal of dermatology · 2026Article
- Review
- Trichophyton mentagrophytes type VII: cohort study on patient characteristics, clinical features, disease course, and treatment.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSexually transmitted infections with Trichophyton mentagrophytes type VII (TMVII) have been reported in several countries. The aim of our study was to identify epidemiological and clinical features in order to improve prevention, diagnosis, and treatment. PATIENTS AND
methodsPatients with culture-confirmed TMVII infection diagnosed between 2020 and 2024 at the Department of Dermatology, Charité - Universitätsmedizin Berlin, Germany, were included. Patient characteristics, clinical presentation, and treatment were assessed.
resultsFifty-one patients were included (96.1% male; median age, 34 years), with 94.6% of male patients reporting male sex partners. Among 47 patients with known HIV status, 19.1% were living with HIV, while 71.1% of HIV-negative patients reported using pre-exposure prophylaxis (PrEP). Median time to diagnosis was 42.5 days (Q1-Q3: 29.25-73.5). Atypical morphologies, such as purulent or infiltrated subcutaneous lesions, occurred in 82.4%, and 96.1% had genital, perianal, or perioral manifestations. Median systemic treatment duration was 83.5 days (Q1-Q3: 57-110.25), with no significant differences by morphology (p = 0.69) or HIV/PrEP status (p = 0.88).
conclusionsTMVII infections often present with atypical morphology and should be considered in the differential diagnosis of genital, perianal, and perioral dermatoses, particularly among men with multiple male partners. Clinicians should anticipate prolonged treatment durations to achieve clearance and prevent recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.